Mediolanum Farmaceutici S.p.A.

What Mediolanum Farmaceutici S.p.A. does

Mediolanum Farmaceutici S.p.A. is a privately-held Italian pharmaceutical holding company founded in 1972 and headquartered in Milan. Through wholly-owned subsidiaries — Istituto Gentili (oncology and onco-hematology), Vamfarma (manufacturing at Comazzo, Lodi), Laboratoires Leurquin (French commercialization), and Mediolanum Biosciences (biotech R&D) — the group develops, licenses, and commercializes molecules in oncology, rare diseases, and adjacent specialty therapeutic areas, operating three production sites across Italy and France and serving both national and international markets.

The group monetizes its platform through a hybrid model that combines in-house product development, licensing-in and licensing-out of molecules, co-development partnerships, and selective acquisitions. Revenue mechanics therefore rest on direct product sales via subsidiaries, royalty and licensing arrangements (the source materials cite licensing/royalties as the headline revenue model type), and commercialization agreements with major pharma such as Novartis Oncology and Teva Italia. The customer base is B2B in nature — healthcare professionals, partner organizations, and patients reached through commercial partners — and pricing is not publicly disclosed.

Strategically, Mediolanum has reshaped its portfolio over the past decade: it acquired Istituto Gentili and Neopharmed from MSD (2009-10), later divested the majority of Neopharmed Gentili to an investment fund (2018), and re-invested in oncology through the 2017 Novartis-affiliated relaunch of Istituto Gentili, the 2017 acquisition of Therabel Gienne Pharma, the 2020 acquisition of French biotech ElsaLys Biotech, and the 2020-21 aromatase inhibitors portfolio acquisition. Non-core subsidiaries Le Fabriche (vineyard/agriculture) and Diomede (real estate) sit within the group but are unrelated to the pharmaceutical mandate.

Name

Mediolanum Farmaceutici S.p.A.

Legal name

Mediolanum Farmaceutici S.p.A.

Website

https://mediolanum-farma.it

Company type

Private

Founded year

1972

Operating status

Operating

Short description

Mediolanum Farmaceutici S.p.A. is an Italian pharmaceutical holding company (founded 1972, Milan) that develops, licenses, and commercializes molecules in oncology and rare diseases through subsidiaries and three production sites in Italy and France.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Pharmaceutical manufacturing
• Oncology drug development
• Rare disease therapies
• Pharmaceutical licensing
• Contract drug production

Headquarters

HQ city

Milan

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical product sales and licensing: The company generates revenue through the development, production, and commercialization of pharmaceutical products. They engage in licensing-in activities, acquisitions, and co-development partnerships for promotion, marketing and commercialization of pharmaceutical products already present on the market. Their business development activities include licensing-in and acquisitions of pharmaceutical products.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Mediolanum Farmaceutici S.p.A. is an Italian pharmaceutical holding company that develops, produces, and commercializes pharmaceutical products focused on oncology and rare diseases. The group operates through subsidiaries (Istituto Gentili, Vamfarma, Laboratoires Leurquin, Mediolanum Biosciences) and runs three production sites in Italy and France covering manufacturing, packaging, and commercialization of drugs for national and international markets. The company engages in licensing-in, acquisitions, and co-development partnerships to promote and commercialize pharmaceutical products.

Product overview

Mediolanum Farmaceutici S.p.A. is a pharmaceutical holding company founded in 1972, operating a portfolio of subsidiaries and production sites across Italy and France. The group's structure centers on Istituto Gentili (oncology and onco-hematology biopharma), Vamfarma (manufacturing and packaging at the Comazzo site), and Laboratoires Leurquin (French commercialization). Additional subsidiaries include Mediolanum Biosciences (biotech), Le Fabriche (vineyard/agriculture), and Diomede (real estate). The company operates in two core therapeutic areas: oncology (including breast cancer, aromatase inhibitors, immuno-oncology) and rare diseases. Business development activities include licensing-in, acquisitions, co-development, promotion, marketing, and commercialization of pharmaceutical products.

Differentiator

Problem solved

Functional benefit

Brands

• Istituto Gentili: Italian biopharma company specializing in development and commercialization of molecules in oncology and onco-hematology
• Vamfarma
• Laboratoires Leurquin
• Mediolanum Biosciences
• Le Fabriche
• Diomede

Products and services

• Istituto Gentili Italian biopharma subsidiary of Mediolanum Farmaceutici that develops and commercializes molecules (both proprietary and in partnership) in oncology and onco-hematology, aimed at improving quality of life and survival for patients with serious neoplasia.
• Vamfarma Production site of the Mediolanum Group at Comazzo (Lodi), dedicated to the production and packaging of different pharmaceutical forms destined for both national and international markets.
• Laboratoires Leurquin French pharmaceutical subsidiary dedicated to the commercialization of drugs and phytotherapy products across several therapeutic areas.
• Mediolanum Biosciences Biotechnology subsidiary of the Mediolanum Group focused on biotechnology and research operations supporting pharmaceutical R&D activities.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core.

• ElsaLys BiotechcoreStrategic or Co-development Partner · 1 January 2020Acquisition of French biotech ElsaLys for the development of advanced immuno-oncological therapies.
• Aromatase Inhibitors PortfoliocoreStrategic or Co-development Partner · 1 January 2020Istituto Gentili acquired the aromatase inhibitors portfolio and a product dedicated to support therapies for oncological patients, expanding the company's answer to breast cancer treatment.
• Teva Italia (OncoCare)coreStrategic or Co-development Partner · 1 January 2018Agreement for commercialization of OncoCare products from Teva Italia, further strengthening Mediolanum's commitment in oncology field.
• Novartis OncologycoreStrategic or Co-development Partner · 1 January 2017Agreement with Novartis Oncology marked the birth of Istituto Gentili, a new reality fully dedicated to oncology. Istituto Gentili became the Italian concessionary for Tyverb (lapatinib), an innovative drug indicated for treatment of HER2-positive breast carcinoma.
• Therabel Gienne PharmacoreStrategic or Co-development Partner · 1 January 2017Acquisition of Therabel Gienne Pharma, the Italian branch of the Dutch Group Therabel.
• MSDcoreStrategic or Co-development Partner · 1 January 2009Acquisition of Istituto Gentili and Neopharmed from MSD.

Scale indicators3 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Recordati S.p.A. Italian specialty pharmaceutical company operating across Europe with focus on rare diseases and specialty therapeutics. Direct comparable as a Milan-headquartered Italian pharma group with similar therapeutic area focus, European commercial footprint, and specialty pharma acquisition strategy.
• Menarini Group: Private Italian pharmaceutical holding company with diversified pharma operations including oncology, specialty therapeutics, and manufacturing. Comparable as an Italian private pharma holding with multiple subsidiaries and similar European distribution model.
• Chiesi Farmaceutici S.p.A. Private Italian pharmaceutical company with focus on specialty therapeutics including rare diseases. Comparable as a privately-held Italian pharma group with strong European presence and similar focus on therapeutic innovation.
• Italfarmaco S.p.A. Private Italian pharmaceutical company specializing in specialty and rare disease therapeutics with manufacturing and commercialization across Europe. Highly comparable as a Milan-based private pharma group with similar specialty focus.
• Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. Private Italian pharmaceutical company with specialty therapeutic focus including oncology and rare diseases. Comparable as an Italian specialty pharma player with similar therapeutic area emphasis and B2B partnership approach.
• Dompé farmaceutici S.p.A. Private Italian biopharmaceutical company with focus on specialty therapeutics and rare diseases including ophthalmology and oncology. Comparable as a privately-held Italian biopharma with R&D and commercial operations.
• Zambon S.p.A. Private Italian pharmaceutical company with operations across multiple therapeutic areas including specialty and rare disease treatments. Comparable as an Italian private pharma group with European footprint and similar subsidiary structure.
• Angelini Industries (Angelini Pharma): Private Italian pharmaceutical group with focus on specialty therapeutics, oncology, and CNS. Comparable as a privately-held Italian pharma group with international presence and similar therapeutic diversification.
• Pierre Fabre Group: French private pharmaceutical company with strong oncology and dermatology focus. Comparable as a French-headquartered pharma group with similar oncology specialty focus and European manufacturing footprint.

Broad incumbents

• Servier Laboratories: Large French private pharmaceutical group with significant oncology franchise and European manufacturing. Comparable as a European private pharma incumbent with overlapping oncology capabilities but at much larger scale and broader portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/mediolanum-farmaceutici-spa

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mediolanum Farmaceutici S.p.A.